Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15414992 | 1.00 | ALDH1A1 (0.42) | ALDH1A1PKMMGLLSMN1; SMN2NPSR1 | |
| SCHEMBL16283418 | 0.98 | ALDH1A1 (0.43) | ALDH1A1PKMMGLLSMN1; SMN2NPSR1 | |
| SCHEMBL18157044 | 0.90 | ALDH1A1 (0.40) | ALDH1A1PKMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30881150 | 0.86 | MGLL (0.40) | ALDH1A1PKMMGLLSMN1; SMN2MEN1 | |
| SCHEMBL26421368 | 0.83 | MGLL (0.36) | ALDH1A1PKMMGLLSMN1; SMN2RAB9A | |
| SCHEMBL15415134 | 0.80 | MGLL (0.42) | ALDH1A1PKMMGLLSMN1; SMN2NPSR1 | |
| SCHEMBL24581861 | 0.79 | ALDH1A1 (0.63) | ALDH1A1PKMNPSR1MEN1KMT2A | |
| SCHEMBL2577129 | 0.79 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A | |
| SCHEMBL21158480 | 0.79 | MGLL (0.33) | ALDH1A1PKMMGLLRAB9A | |
| SCHEMBL29631632 | 0.79 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023131219-A1 | CONJUGATES, COMPOSITIONS AND METHODS OF USE | VIRTUOSO BINCO, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| EP-3209334-A2 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Igenica Biotherapeutics, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | ALDH1A1 927/4885PKM 4106/4885MGLL 4205/4885 |
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYTH3, CD47, FCGRT | ALDH1A1 2978/4885PKM 4546/4885MGLL 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.